×

ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients

Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years […] The post ECTRIMS 2025: Frexalimab shows long-term benefits for MS patients appeared first on…

ECTRIMS 2025: Ultra-processed foods may fuel disease in early MS

Consuming large amounts of ultra-processed foods (UPF) — products high in additives, artificial ingredients, and extensive processing — is associated with increased disease activity in people with clinically isolated syndrome […] The post ECTRIMS 2025: Ultra-processed foods may fuel disease in early MS appeared first…

Amanda Chavez – MSAA’s October 2025 Artist of the Month

MSAA features the work of many talented artists affected by multiple sclerosis as part of our annual MSAA Art Showcase. Each month we share these artists’ inspiring stories and beautiful artwork with you as our Artist of the Month. This month, we celebrate Amanda … Continue reading → Source:…

ECTRIMS 2025: Eque-cel shown to ease disability in progressive MS

Treatment with equecabtagene autoleucel, known for short as eque-cel — Iaso Biotherapeutics‘ CAR T-cell therapy candidate for people with progressive forms of multiple sclerosis (MS) — was well tolerated and […] The post ECTRIMS 2025: Eque-cel shown to ease disability in progressive MS appeared first…

ECTRIMS 2025: Drug combo shows promise for myelin repair in trial

Combining the diabetes medication metformin and the antihistamine clemastine significantly increased myelin repair in people with relapsing-remitting multiple sclerosis (RRMS), according to results from a Phase 2 clinical trial. However, […] The post ECTRIMS 2025: Drug combo shows promise for myelin repair in trial appeared…

ECTRIMS 2025: High-dose Vitamin D reduces MS activity, study finds

Increasing blood vitamin D levels with high-dose supplementation can significantly reduce the risk of new disease activity in people with clinically isolated syndrome (CIS), or those who experienced a first […] The post ECTRIMS 2025: High-dose Vitamin D reduces MS activity, study finds appeared first…